Autonomix Medical, Inc. is a medical device company, which is focused on advancing technologies to treat diseases involving the peripheral nervous system. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. It is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.
BörsenkürzelAMIX
Name des UnternehmensAutonomix Medical Inc
IPO-datumJan 29, 2024
CEOMr. Bradley (Brad) Hauser
Anzahl der mitarbeiter8
WertpapierartOrdinary Share
GeschäftsjahresendeJan 29
Addresse21 Waterway Ave, Suite 300
StadtTHE WOODLANDS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl77380
Telefon18322777816
Websitehttps://autonomix.com/
BörsenkürzelAMIX
IPO-datumJan 29, 2024
CEOMr. Bradley (Brad) Hauser
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten